Patent application number | Description | Published |
20130224782 | NEUROGENESIS SCREENING METHOD AND SYSTEM USING ADIPOSE TISSUE DERIVED STEM CELLS - Provided herein are methods for identifying a neurogenesis-modulating compound, comprising: culturing adipose-derived stem cells (ADSCs) in the presence of a candidate compound; and determining the extent of neurogenesis in the ADSCs and systems for identifying a neurogenesis modulating compound. Also provided are methods of promoting neurogenesis in ADSCs. | 08-29-2013 |
20130224862 | COATINGS AND CULTURE MEDIA FOR PROMOTING NEUROGENESIS IN ADIPOSE TISSUE DERIVED STEM CELLS - Provided herein are coatings for stem cell cultureware comprising poly-L-ornithine and bovine fibronectin and methods for preparing coated stem cultureware comprising contacting cultureware with poly-L-ornithine and contacting the cultureware with bovine fibronectin. Also provided are stem cell culture media comprising epidermal growth factor, beta-fibroblast growth factor and N2 supplement. | 08-29-2013 |
20140107193 | NUTRITIONAL COMPOSITION CONTAINING A NEUROLOGIC COMPONENT OF KAEMPFEROL AND/OR FISETIN AND USES THEREOF - The present disclosure generally relates to nutritional compositions that are suitable for administration to adult and pediatric subjects that include a neurologic component. The neurologic component may include a flavonoid compound, such as kaempferol, fisetin, or both, and provides beneficial health benefits such as enhanced brain development and improved memory, cognition, hand-eye coordination, and enhanced focusing. Furthermore, the neurologic component may act synergistically with other brain nutrients that may be present in the compositions. | 04-17-2014 |
20140179656 | NEUROGENESIS SCREENING METHOD AND USES THEREOF - Provided herein are methods for detecting and/or confirming the neurogenesis effect of cholesterol and/or oxysterol utilizing adipose-derived stem cells (ADSCs). Further provided are methods of promoting neurogenesis in ADSCs. Also provided are methods for the use of cholesterol and/or oxysterol for the production of a neurologic component that may be incorporated into a nutritional composition for promoting neurogenesis in a pediatric subject. | 06-26-2014 |
20140179775 | NEUROGENESIS SCREENING METHOD AND USES THEREOF - Provided herein are methods for detecting and/or confirming the neurogenesis effect of EGCG and/or resveratrol utilizing adipose-derived stem cells (ADSCs). Further provided are methods of promoting neurogenesis in ADSCs. Also provided are methods for the use of EGCG and/or resveratrol for the production of a neurologic component that may be incorporated into a nutritional composition for promoting neurogenesis in a pediatric subject. | 06-26-2014 |
20140179782 | NEUROGENESIS SCREENING METHOD AND USES THEREOF - Provided herein are methods for detecting and/or confirming the neurogenesis effect of eicosapentaenoic acid utilizing adipose-derived stem cells (ADSCs). Further provided are methods of promoting neurogenesis in ADSCs. Also provided are methods for the use of eicosapentaenoic acid for the production of a neurologic component that may be incorporated into a nutritional composition for promoting neurogenesis in a pediatric subject. | 06-26-2014 |
20140199265 | NUTRITIONAL COMPOSITIONS CONTAINING A NEUROLOGIC COMPONENT AND USES THEREOF - The present disclosure relates to nutritional compositions comprising a neurologic component, wherein, the neurologic component may promote brain and nervous system development and further provide neurological protection and repair. The neurologic component may include phosphatidylethanolamine, sphingomyelin, cytidine diphosphate-choline, ceramide, uridine, at least one ganglioside, and mixtures thereof. The disclosure further relates to methods of promoting brain and nervous system health by providing said nutritional compositions to target subjects, which includes pediatric subjects. | 07-17-2014 |
20150023922 | METHODS FOR PROMOTING NEURONAL DEVELOPMENT AND/OR HEALTH - The present disclosure relates to methods for promoting neuronal health and/or development in a subject by providing nutritional compositions comprising a neurologic component, wherein the neurologic component may promote brain and nervous system development and further provide neurological protection and repair. The neurologic component may include lactoferrin, zine sulfate, one or more organosulfur compound, and mixtures thereof. | 01-22-2015 |
20150023923 | METHODS FOR PROMOTING NEURONAL DEVELOPMENT AND/OR HEALTH - The present disclosure relates to methods for promoting neuronal health and/or development in a subject by providing nutritional compositions comprising docosahexaenoic acid and alpha-lipoic acid. The nutritional composition may further include lactoferrin, a prebiotic, a probiotic, and mixtures thereof. Additionally the present disclosure provides methods for accelerating the development of neuronal activity and/or strengthening electrochemical synapse signaling by providing the nutritional composition(s) disclosed herein to a target subject. | 01-22-2015 |
Patent application number | Description | Published |
20090302894 | DUAL GATE TRANSISTOR KEEPER DYNAMIC LOGIC - A dynamic logic gate has a device for charging a dynamic node during a pre-charge phase of a clock. A logic tree evaluates the dynamic node with a device during an evaluate phase of the clock. The dynamic node has a keeper circuit comprising an inverter with its input coupled to the dynamic node and its output coupled to the back gate of a dual gate PFET device. The source of the dual gate PFET is coupled to the power supply and its drain is coupled to the dynamic node forming a half latch. The front gate of the dual gate PFET is coupled to a logic circuit with a mode input and a logic input coupled back to a node sensing the state of the dynamic node. The mode input may be a slow mode to preserve dynamic node state or the clock delayed that turns ON the strong keeper after evaluation. | 12-10-2009 |
20090302929 | Methods and Apparatus for Varying a Supply Voltage or Reference Voltage Using Independent Control of Diode Voltage in Asymmetrical Double-Gate Devices - Methods and apparatus are provided for varying one or more of a supply voltage and reference voltage in an integrated circuit, using independent control of a diode voltage in an asymmetrical double-gate device. An integrated circuit is provided that is controlled by one or more of a supply voltage and a reference voltage. The integrated circuit comprises an independently controlled asymmetrical double-gate device to adjust one or more of the supply voltage and the reference voltage. The independent control may comprise, for example, a back gate bias. The independently controlled asymmetrical double-gate device may be employed in a number of applications, including voltage islands, static RAM, and to improve the power and performance of a processing unit. | 12-10-2009 |
20090303778 | Methods and Apparatus for Varying a Supply Voltage or Reference Voltage Using Independent Control of Diode Voltage in Asymmetrical Double-Gate Devices - Methods and apparatus are provided for varying one or more of a supply voltage and reference voltage in an integrated circuit, using independent control of a diode voltage in an asymmetrical double-gate device. An integrated circuit is provided that is controlled by one or more of a supply voltage and a reference voltage. The integrated circuit comprises an independently controlled asymmetrical double-gate device to adjust one or more of the supply voltage and the reference voltage. The independent control may comprise, for example, a back gate bias. The independently controlled asymmetrical double-gate device may be employed in a number of applications, including voltage islands, static RAM, and to improve the power and performance of a processing unit. | 12-10-2009 |
20100001766 | SYSTEM TO EVALUATE A VOLTAGE IN A CHARGE PUMP AND ASSOCIATED METHODS - A system to evaluate a voltage in a charge pump may include a transistor, and a transistor drain carried by the transistor with the transistor drain receiving a reference current. The system may also include a transistor gate carried by the transistor and connected to the transistor drain. The system may further include an additional transistor and an additional transistor gate carried by the additional transistor and connected to the transistor gate. The system may additionally include an additional transistor drain to receive the reference current mirrored from the additional transistor. | 01-07-2010 |
20120205721 | Design Structure for High Density Stable Static Random Access Memory - A design structure tangibly embodied in a machine readable medium for designing, manufacturing, or testing an integrated circuit includes a plurality of bit line structures, a plurality of word line structures intersecting said plurality of bit line structures to form a plurality of cell locations, and a plurality of cells located at said plurality of cell locations, each of said cells being selectively coupled to a corresponding bit line structure under control of a corresponding word line structure, each of said cells comprising a logical storage element having at least a first n-type field effect transistor and at least a first p-type field effect transistor, wherein said at least first n-type field effect transistor is formed with a relatively thick buried oxide layer sized to reduce capacitance of said bit line structures, and said at least first p-type field effect transistor is formed with a relatively thin buried oxide layer. | 08-16-2012 |
Patent application number | Description | Published |
20100043551 | Method and Apparatus for a Micromachined Multisensor - In a micromachined devices having a movable shuttle driven in oscillation, measuring the electrical charge accumulated on opposing drive capacitors to determine the displacement of the movable shuttle. Alternately, in such a micromachined device, measuring the electrical charge accumulated on a drive capacitor and comparing the measured electrical charge to a nominal electrical charge to determine the displacement of the movable shuttle. | 02-25-2010 |
20100058861 | Piezoelectric Transducers and Inertial Sensors using Piezoelectric Transducers - Transducers comprising a frame structure made of piezoelectric material convert energy, through piezoelectric effect, between electrostatic energy associated with voltage differential between the electrodes sandwiching the frame structure and mechanical energy associated with deformation of the frame structure. Inertial sensors such as gyroscopes and accelerators, including inertial sensors comprising ring resonators, utilize said transducers both to generate oscillations of their resonators and to sense the changes in such oscillations produced, in the sensors' frame of reference, by Coriolis forces appearing due to the movement of the sensors. | 03-11-2010 |
20110030474 | Inertial Sensors with Reduced Sensitivity to Quadrature Errors and Micromachining Inaccuracies - Inertial sensors with reduced sensitivity to quadrature errors and micromachining inaccuracies include a gyroscope incorporating two specially-configured single-axis gyroscopes for sensing rotations about two orthogonal axes (the axes of sensitivity) in the device plane, where each single-axis gyroscope includes a resonator having two rotationally-dithered shuttles interconnected by a fork and each shuttle is configured to tilt out-of-plane along a tilt axis perpendicular to the axis of sensitivity and includes corresponding Coriolis sensing electrodes positioned along an axis perpendicular to the tilt axis (i.e., parallel to the axis of sensitivity). The two single-axis gyroscopes may be interconnected, e.g., by one or more in-phase or anti-phase couplings interconnecting the forks and/or the shuttles. | 02-10-2011 |
20120210790 | Piezoelectric Transducers and Inertial Sensors using Piezoelectric Transducers - An inertial sensor includes driving piezoelectric transducers for enabling an oscillation of a resonator, sensing piezoelectric transducers for enabling a detection of a movement of the inertial sensor, and piezoelectric compensating elements substantially equidistantly among the driving and the sensing piezoelectric transducers, wherein the compensating elements and the resonator form corresponding capacitors having capacitive gaps, and wherein, during the oscillation of the resonator, changes in electrostatic charges stored in the capacitors are measured with the compensating elements and are modified so as to modify the oscillation of the resonator. | 08-23-2012 |
20130167639 | Inertial Sensors Using Piezoelectric Transducers - An inertial sensor includes driving piezoelectric transducers for enabling an oscillation of a resonator, sensing piezoelectric transducers for enabling a detection of a movement of the inertial sensor, and piezoelectric compensating elements substantially equidistantly among the driving and the sensing piezoelectric transducers, wherein the compensating elements and the resonator form corresponding capacitors having capacitive gaps, and wherein, during the oscillation of the resonator, changes in electrostatic charges stored in the capacitors are measured with the compensating elements and are modified so as to modify the oscillation of the resonator. | 07-04-2013 |
20130167642 | Piezoelectric Transducers - An inertial sensor includes driving piezoelectric transducers for enabling an oscillation of a resonator, sensing piezoelectric transducers for enabling a detection of a movement of the inertial sensor, and piezoelectric compensating elements substantially equidistantly among the driving and the sensing piezoelectric transducers, wherein the compensating elements and the resonator form corresponding capacitors having capacitive gaps, and wherein, during the oscillation of the resonator, changes in electrostatic charges stored in the capacitors are measured with the compensating elements and are modified so as to modify the oscillation of the resonator. | 07-04-2013 |
Patent application number | Description | Published |
20110206776 | METHODS OF MANUFACTURE OF IMMUNOCOMPATIBLE AMNIOTIC MEMBRANE PRODUCTS - Provided herein is a placental product comprising an immunocompatible amniotic membrane. Such placental products can be cryopreserved and contain viable therapeutic cells after thawing. The placental product of the present invention is useful in treating a patient with a tissue injury (e.g. wound or burn) by applying the placental product to the injury. Similar application is useful with ligament and tendon repair and for engraftment procedures such as bone engraftment. | 08-25-2011 |
20110212063 | METHODS OF MANUFACTURE OF IMMUNOCOMPATIBLE CHORIONIC MEMBRANE PRODUCTS - Provided herein is a placental product comprising an immunocompatible chorionic membrane. Such placental products can be cryopreserved and contain viable therapeutic cells after thawing. The placental product of the present invention is useful in treating a patient with a tissue injury (e.g. wound or burn) by applying the placental product to the injury. Similar application is useful with ligament and tendon repair and for engraftment procedures such as bone engraftment. | 09-01-2011 |
20110212158 | IMMUNOCOMPATIBLE CHORIONIC MEMBRANE PRODUCTS - Provided herein is a placental product comprising an immunocompatible chorionic membrane. Such placental products can be cryopreserved and contain viable therapeutic cells after thawing. The placental product of the present invention is useful in treating a patient with a tissue injury (e.g. wound or burn) by applying the placental product to the injury. Similar application is useful with ligament and tendon repair and for engraftment procedures such as bone engraftment. | 09-01-2011 |
20110256202 | IMMUNOCOMPATIBLE AMNIOTIC MEMBRANE PRODUCTS - Provided herein is a placental product comprising an immunocompatible amniotic membrane. Such placental products can be cryopreserved and contain viable therapeutic cells after thawing. The placental product of the present invention is useful in treating a patient with a tissue injury (e.g. wound or burn) by applying the placental product to the injury. Similar application is useful with ligament and tendon repair and for engraftment procedures such as bone engraftment. | 10-20-2011 |
20140017283 | PORATED CARTILAGE PRODUCTS - This invention provides porated cartilage products, methods of producing porated cartilage products, and methods of treating subjects by administering cartilage products. Optionally, the cartilage products are sized, porated, and digested to provide a flexible cartilage product. Optionally, the cartilage products comprise viable chondrocytes, bioactive factors such as chondrogenic factors, and a collagen type II matrix. Optionally, the cartilage products are non-immunogenic. | 01-16-2014 |
20140017292 | METHODS OF MANUFACTURING CARTILAGE PRODUCTS - This invention provides porated cartilage products and methods of producing porated cartilage products. Optionally, the cartilage products are sized, porated, and digested to provide a flexible cartilage product. Optionally, the cartilage products comprise viable chondrocytes, bioactive factors such as chondrogenic factors, and a collagen type II matrix. Optionally, the cartilage products are non-immunogenic. | 01-16-2014 |
20140030309 | DISRUPTED CARTILAGE PRODUCTS - This invention provides disrupted cartilage products, methods of manufacturing disrupted cartilage products, and methods of treating a subject comprising administering a cartilage product. The cartilage products are manufactured by a method comprising disrupting a collagen matrix, e.g. to produce a flexible cartilage product. Optionally, the cartilage products comprise viable chondrocytes, bioactive factors such as chondrogenic factors, and a collagen type II matrix. Optionally, the cartilage products are non-immunogenic. | 01-30-2014 |
20140127177 | Methods of Manufacture of Therapeutic Products Comprising Vitalized Placental Dispersions - This invention provides a fluid therapeutic placental product comprising placental cells and a placental dispersion comprising placental factors. The placental cells and the placental dispersion are derived from placental tissue. A placental tissue can optionally be an amnion, chorion, or a trophoblast-depleted chorion. The placental product of the present invention is useful in treating a patient with a tissue injury (e.g. wound or burn) by applying the placental product to the injury. Similar application is useful with ligament and tendon repair and for engraftment procedures such as bone engraftment. | 05-08-2014 |
20140140966 | Methods of Manufacture of Immunocompatible Chorionic Membrane Products - Provided herein is a placental product comprising an immunocompatible chorionic membrane. Such placental products can be cryopreserved and contain viable therapeutic cells after thawing. The placental product of the present invention is useful in treating a patient with a tissue injury (e.g. wound or burn) by applying the placental product to the injury. Similar application is useful with ligament and tendon repair and for engraftment procedures such as bone engraftment. | 05-22-2014 |
20140294777 | IMMUNOCOMPATIBLE AMNIOTIC MEMBRANE PRODUCTS - Provided herein is a placental product comprising an immunocompatible amniotic membrane. Such placental products can be cryopreserved and contain viable therapeutic cells after thawing. The placental product of the present invention is useful in treating a patient with a tissue injury (e.g. wound or burn) by applying the placental product to the injury. Similar application is useful with ligament and tendon repair and for engraftment procedures such as bone engraftment. | 10-02-2014 |
20140301986 | IMMUNOCOMPATIBLE CHORIONIC MEMBRANE PRODUCTS - Provided herein is a placental product comprising an immunocompatible chorionic membrane. Such placental products can be cryopreserved and contain viable therapeutic cells after thawing. The placental product of the present invention is useful in treating a patient with a tissue injury (e.g. wound or burn) by applying the placental product to the injury. Similar application is useful with ligament and tendon repair and for engraftment procedures such as bone engraftment. | 10-09-2014 |
20150017222 | Disrupted Cartilage Products - This invention provides disrupted cartilage products, methods of manufacturing disrupted cartilage products, and methods of treating a subject comprising administering a cartilage product. The cartilage products are manufactured by a method comprising disrupting a collagen matrix, e.g. to produce a flexible cartilage product. Optionally, the cartilage products comprise viable chondrocytes, bioactive factors such as chondrogenic factors, and a collagen type II matrix. Optionally, the cartilage products are non-immunogenic. | 01-15-2015 |
20150140057 | PORATED CARTILAGE PRODUCTS - This invention provides porated cartilage products, methods of producing porated cartilage products, and methods of treating subjects by administering cartilage products. Optionally, the cartilage products are sized, porated, and digested to provide a flexible cartilage product. Optionally, the cartilage products comprise viable chondrocytes, bioactive factors such as chondrogenic factors, and a collagen type II matrix. Optionally, the cartilage products are non-immunogenic. | 05-21-2015 |
20150259119 | SUPPORT AND PACKAGING FOR MEMBRANES - A support assembly for supporting a biological product (e.g., membrane) in an operative position. The support assembly has a base and a cover. A membrane receiving portion of the base defines a plurality of perforations that extend between top and bottom surfaces of the product receiving portion. The cover is releasably coupled to the base in a product-covering position in which the cover overlies the product receiving portion of the base. In the operative position, the biological product engages the top surface of the product receiving portion and the bottom surface of the cover. | 09-17-2015 |
Patent application number | Description | Published |
20080243325 | OPTIMAL ENGINE OPERATING POWER MANAGEMENT STRATEGY FOR A HYBRID ELECTRIC VEHICLE POWERTRAIN - A method is disclosed for managing power in a hybrid electric vehicle powertrain having multiple components, including an engine, a motor, a generator and a high voltage battery. Power losses in the individual components are computed. An engine speed corresponding to a minimum value for the power losses is selected to achieve optimal total powertrain efficiency. | 10-02-2008 |
20080270016 | Navigation System for a Vehicle - A navigation system and method provides travel routes for a vehicle The method includes receiving an origin ( | 10-30-2008 |
20110010032 | Optimal Engine Operating Power Management Strategy for a Hybrid Electric Vehicle Powertrain - A method is disclosed for managing power in a hybrid electric vehicle powertrain having multiple components, including at least two of a group comprising an engine, a motor, a generator and a high voltage battery. Power losses in the individual components are computed. An engine operating speed and torque for a given vehicle speed and total power command is determined so that total power losses for powertrain components are minimized. | 01-13-2011 |
20120059565 | OPTIMAL ENGINE OPERATING POWER MANAGEMENT STRATEGY FOR A HYBRID ELECTRIC VEHICLE POWERTRAIN - A method for managing power in a hybrid electric vehicle powertrain having multiple components including at least two of a group comprising an engine, a motor, a generator and a high voltage battery includes computing power losses for the individual components. An engine operating speed and torque for a given vehicle speed and total power command is determined so that total power losses for powertrain components are minimized. | 03-08-2012 |
Patent application number | Description | Published |
20090250277 | Battery Equalization Using a Plug-In Charger in a Hybrid Electric Vehicle - In a hybrid electric motor vehicle , a power supply system for storing and supplying electrical power includes a motor-generator located onboard the vehicle, driveably connected to the vehicle wheels and producing AC electric power, an energy storage device for alternately storing and discharging electric power, an inverter coupled to the motor-generator and the energy storage device for converting alternating current produced by the motor-generator to direct current transmitted to the energy storage device, and for converting direct current stored in the energy storage device to alternating current transmitted to the motor-generator, an off board source of AC electric power located external to the vehicle, and a charger coupled to said electric power source and the energy storage device for supplying DC electric power to the energy storage device from said AC electric power source. | 10-08-2009 |
20110166732 | DISTANCE BASED BATTERY CHARGE DEPLETION CONTROL FOR PHEV ENERGY MANAGEMENT - In a plug-in hybrid electric vehicle (PHEV), the vehicle may be operated in a charge-(CD) mode to ensure that the battery is effectively discharged or in a charge-sustaining (CS) mode in which the battery state of charge is maintained by operating the internal combustion engine predominantly for propulsion. In trips that are longer than that which fully depletes the battery storage, it is possible to control the proportion in a manner that is between CS and CD modes to provide overall higher efficiency while still effectively discharging the battery over the course of the trip. Such higher efficiency operation is possible when information about the distance until the next charging event is available. | 07-07-2011 |
20120022731 | Series-Drive Operation During Launch and Creep of a Hybrid Electric Vehicle - A method for launching a vehicle includes determining that vehicle speed is less than a reference, demanded wheel power is less than a reference wheel power, and demanded engine power is less than a reference engine power; charging a battery using a generator driven by an engine; using an electric machine powered by the battery to drive vehicle wheels; and opening a clutch located in a drive path between a transmission and the generator. | 01-26-2012 |
20130035186 | Reconfigurable Powersplit Powertrain for an Electric Vehicle - A powertrain includes a gearset including a sun gear, a carrier, a ring gear connected to a countershaft, pinions supported on the carrier and meshing with the sun gear and ring gear; a second gearset connectable to an engine, for overdriving a generator; a clutch for releasably connecting the engine and carrier; a second clutch for releasably connecting the sun gear and the generator; and a motor connected to a countershaft. Operation of the powertrain can be readily switched between powersplit mode and series mode. | 02-07-2013 |
20150105214 | Coordinating Regenative Braking with Torque Converter Clutch Operation - A method for controlling a vehicle regenerative braking event includes maintaining a converter clutch closed while braking, while an engine connected to the impeller is running, opening the converter clutch when impeller speed reaches a reference speed difference relative to engine idle speed, and while the engine is off, opening the converter clutch when impeller speed reaches a speed required for a transmission pump, connected to an impeller, to produce line pressure at a desired magnitude. | 04-16-2015 |
20150232086 | SMOOTHING HYBRID VEHICLE ENGINE SHUTDOWN - A method of smoothing hybrid vehicle engine shutdown. A powered and rotating electric machine is used to slow deceleration of an unpowered and rotating engine by transferring torque through a clutch from the machine to the unpowered engine. Prior to the machine being powered, torque may be transferred through the clutch from the unpowered and rotating engine to the unpowered machine to accelerate passage of the engine through a resonance frequency. | 08-20-2015 |
20150258974 | Stopping a Hybrid Engine with Engine Start Anticipation - A hybrid electric automotive powertrain includes an engine start/stop system to improve fuel economy. The stop routine provides for quick restarting to avoid delay in a driver change of mind case. The stop routine may be terminated prior to full engine stop when a torque request is received during the stop routine. | 09-17-2015 |
20150283988 | LIMITING REGENERATIVE TORQUE FOR A HYBRID ELECTRIC POWERTRAIN - Regenerative torque is limited for a hybrid electric powertrain of a vehicle. A transmission controller determined torque limit is validated by a vehicle controller. The vehicle controller validates the torque limit using, individually or in combination, an actual status of a torque converter clutch, a detected status of the torque converter clutch, or a speed of the vehicle. | 10-08-2015 |
20150283989 | CLUTCH CALIBRATION FOR A HYBRID ELECTRIC POWERTRAIN - Calibration of an engine disconnect clutch for a hybrid electric powertrain. The clutch is prestroked while an engine and machine are stopped. A machine torque is increased until the machine starts rotating. A pressure of the clutch is adjusted as a function of a torque produced by the machine when the machine started rotating. | 10-08-2015 |
Patent application number | Description | Published |
20100239479 | Process For Removing Toxic Metals From A Fluid Stream - A process for removing at least one of As, Cd, Hg and Se from a fluid stream, comprising: (I) providing a plurality of Group A particles of a Group A sorbent material, said Group A sorbent material comprising: an activated carbon matrix defining a plurality of pores; sulfur; and an additive adapted for promoting the removal of at least one of As, Cd, Hg and Se from a fluid stream, wherein the additive is distributed throughout the activated carbon matrix; and (II) contacting the fluid stream with a plurality of Group A particles of the Group A sorbent material. The process can involve powder injection, a packed sorbent bed, a fluidized sorbent bed, and combinations thereof. | 09-23-2010 |
20110020202 | SORBENT BODIES COMPRISING ACTIVATED CARBON, PROCESSES FOR MAKING THEM, AND THEIR USE - Sorbent bodies comprising activated carbon, processes for making them, and methods of using them. The sorbent bodies can be used to remove toxic elements from a fluid, such as from a gas stream. For instance, the sorbent bodies may be used to remove elemental mercury or mercury in an oxidized state from a coal combustion flue gas. | 01-27-2011 |
Patent application number | Description | Published |
20090170861 | Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors - In its many embodiments, the present invention provides -substituted pyridazinone compounds as glucan synthase inhibitors, methods of preparing such compounds, pharmaceutical including one or more of such compounds, methods of preparing pharmaceutical formulations including one or more such compounds or one or more such compounds along with other antifungal agents, and methods of treatment, prevention, inhibition, or amelioration of one or more fungal infections associated with glucan synthase using such compounds or pharmaceutical compositions. | 07-02-2009 |
20110224136 | INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE - The present invention relates to novel heterocyclic compounds as diacylglycerol acyltransferase (“DGAT”) inhibitors, pharmaceutical compositions comprising the heterocyclic compounds and the use of the compounds for treating or preventing a cardiovascular disease, a metabolic disorder, obesity or an obesity-related disorder, diabetes, dyslipidemia, a diabetic complication, impaired glucose tolerance or impaired fasting glucose. An illustrative compound of the invention is shown below. | 09-15-2011 |
20110224137 | INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE - The present invention relates to novel heterocyclic compounds as diacylglycerol acyltransferase (“DGAT”) inhibitors, pharmaceutical compositions comprising the heterocyclic compounds and the use of the compounds for treating or preventing a cardiovascular disease, a metabolic disorder, obesity or an obesity-related disorder, diabetes, dyslipidemia, a diabetic complication, impaired glucose tolerance or impaired fasting glucose. An illustrative compound of the invention is shown below: formula (I). | 09-15-2011 |
20110224193 | INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE - The present invention relates to novel heterocyclic compounds as diacylglycerol acyltransferase (“DGAT”) inhibitors, pharmaceutical compositions comprising the heterocyclic compounds and the use of the compounds for treating or preventing a cardiovascular disease, a metabolic disorder, obesity or an obesity-related disorder, diabetes, dyslipidemia, a diabetic complication, impaired glucose tolerance or impaired fasting glucose. An illustrative compound of the invention is shown with this abstract. | 09-15-2011 |
20110251207 | BIARYL-SPIROAMINOOXAZOLINE ANALOGUES AS ALPHA 2C ADRENERGIC RECEPTOR MODULATORS - In its many embodiments, the present invention provides a novel class of biaryi spiroaminooxazoline analogues as modulators of α2C adrenergic receptor agonists, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more conditions associated with the α2C adrenergic receptors using such compounds or pharmaceutical compositions. | 10-13-2011 |
20130045914 | BIARYL SPIROAMINOOXAZOLINE ANALOGUES AS ALPHA2C ADRENERGIC RECEPTOR MODULATORS - In its many embodiments, the present invention provides a novel class of biaryl spiroaminooxazoline analogues as modulators of α2C adrenergic receptor agonists, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more conditions associated with the α2C adrenergic receptors using such compounds or pharmaceutical compositions. | 02-21-2013 |
20130225582 | BIARYL-SPIROAMINOOXZAOLINE ANALOGUES AS ALPHA 2C ADRENERGIC RECEPTOR MODULATORS - In its many embodiments, the present invention provides a novel class of biaryl spiroaminooxazoline analogues as modulators of α2C adrenergic receptor agonists, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more conditions associated with the α2C adrenergic receptors using such compounds or pharmaceutical compositions. | 08-29-2013 |
20140088124 | IMIDAZOLE DERIVATIVES - Described herein are compounds of formula (I), The compounds of formula I act as DGAT1 inhibitors and can be useful in preventing, treating or acting as a remedial agent for hyperlipidemia, diabetes mellitus and obesity. | 03-27-2014 |
20150361098 | HETEROBICYCLO-SUBSTITUTED [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES - Disclosed are compounds of Formula G1 (structurally represented): where “RG3” “Rd1” to “Rd4”, “n”, “m”, “p”, “W”, “X”, “Y”, and “Z” are defined herein which compounds are antagonists of A2A receptor. Disclosed herein also are uses of the compounds described herein as antagonists of the A2a receptor in the potential treatment or prevention of neurological disorders and diseases in which A2A receptors are involved. Disclosed herein also are pharmaceutical compositions comprising these compounds and uses of these pharmaceutical compositions. | 12-17-2015 |
Patent application number | Description | Published |
20080312288 | SOLID FORMS OF 2-CHLORO-4-[1-(4-FLUORO-PHENYL)-2,5-DIMETHYL-1H-IMIDAZOL-4-YLETHYNYL]-PYRIDINE - The present invention relates to the mono-sulfate salt, crystalline forms A and B of the mono-sulfate salt, an amorphous form of the mono-sulfate salt, hemi-sulfate salts, and a crystalline form A of the hemi-sulfate salt of the compound 2-chloro-4-[1-(4-fluoro-phenyl)-2,5-dimethyl-1H-imidazol-4-ylethynyl]-pyridine. | 12-18-2008 |
20100076191 | PROCESS FOR PREPARING TRIAZOLE SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES AND NOVEL SALT FORMS PRODUCED THEREIN - A process is provided for preparing triazole substituted azaindoleoxoacetic piperazine derivative. Novel intermediates produced in the above process, and novel N-1 and amorphous forms of a 1,2,3-triazole substituted azaindoloxoacetic piperazine derivatives and processes for producing such novel forms are also provided. | 03-25-2010 |
20100292246 | FORMULATIONS OF 1-(4-BENZOYL-PIPERAZIN-1-YL)-2-[4-METHOXY-7-(3-METHYL-[1,2,4]TRIAZOL-1-YL- )-1H-PYRROLO[2,3-C]PYRIDIN-3-YL]-ETHANE-1,2-DIONE - The instant invention provides formulations of 1-(4-benzoyl-piperazin-1-yl)-2-[4-methoxy-7-(3-methyl-[1,2,4]triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-ethane-1,2-dione; processes for the production of such formulations; and methods of treating HIV or AIDS with such crystalline materials or such formulations. | 11-18-2010 |
20110172428 | METHODS FOR THE PREPARATION OF INDAZOLE-3-CARBOXYLIC ACID AND N-(S)-1-AZABICYCLO[2.2.2]OCT-3-YL-1H-INDAZOLE-3-CARBOXAMIDE HYDROCHLORIDE SALT - The present invention provides novel methods for preparing indazole-3-carboxylic acid 2, a key starting material for the manufacture of agonists or partial agonists of the nicotinic α-7 receptor, such as N—(S)-1-azabicyclo[2.2.2]oct-3-yl-1H-indazole-3-carboxamide HCl salt 13. Nicotinic α-7 receptor agonists and partial agonists are being useful in the treatment of disease conditions associated with defective or malfunctioning nicotinic acetylcholine receptors, especially of the brain, such as for the treatment of Alzheimer's disease and schizophrenia, as well as other psychiatric and neurological disorders. The present methods are useful for preparing indazole-3-carboxylic acid on scaled-up levels. | 07-14-2011 |
20120035222 | Solid forms of 2-Chloro-4-[1-(4-fluoro-phenyl)-2,5-dimethyl-1H-imidazol-4-ylethynyl]-pyr- idine - The present invention relates to mono-sulfate and hemi-sulfate salts of 2-Chloro-4-[1-(4-fluoro-phenyl)-2,5-dimethyl-1H-imidazol-4-ylethynyl]-pyridine, to crystalline and amorphous forms thereof and to their use in pharmaceutical formulations. | 02-09-2012 |
20140039002 | SOLID FORMS OF A PHARMACEUTICALLY ACTIVE SUBSTANCE - The present invention provides solid forms of the compound of formula 1 and pharmaceutical uses thereof. (I) | 02-06-2014 |
Patent application number | Description | Published |
20090031407 | Method and system for security check or verification - An security check or verification method includes generating at least one verification code or number for each user at a security check/verification server, sending the generated verification code or number to user's dedicated mobile device though a secured connection, entering the verification code when user login to a web site, sending the verification code or number to the security check server from the web site server, allowing the user access based on the correct user name, password, and the confirmation form the security check server. | 01-29-2009 |
20100088314 | Method and system for searching on internet - The present invention provides methods and systems for presenting users a search results with choices to display the results in a different sorting or ranking orders. The two or more sets of search results in a different sorting or ranking orders are displayed in the same page. The present invention provides methods and systems to assign truthiness scores to news, messages, or stories. | 04-08-2010 |
20100175102 | Interactive media system - An interactive media system includes a broadcasting device for broadcasting TV signals, and a receiving device for receiving TV signals. The TV signals, such as a TV commercial for new movie preview, contain screen related action codes that include device type, action type and the detail action information. The receiving device includes storage for storing the reference address for other home electronic devices, and a button on a remote controller for the users to start interactive with the interactive media system. When the user presses the button, the receiving device will send the action codes to the designated other home device or another TV screen channel, to allow users to perform the action on the other home device instead of performing the action on TV. The system also allows users just use number keys to navigate web. | 07-08-2010 |